IBEX 35
11.132,00 +26,50 (+0,24%) Euro Stoxx 50
5.077,64 -7,44 (-0,15%) Dólar/Euro
1,0803 +0,0030 (+0,28%) Petróleo Brent
83,60 +0,81 (+0,98%) Oro
2.350,40 -24,60 (-1,04%) Bitcoin EUR
58.275,00 +1.569,29 (+2,77%)
ARYx Therapeutics, Inc. (ARYX)
ARYx Therapeutics, Inc.
6300 Dumbarton Circle
Fremont, CA 94555
United States
510 585 2200
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 56
Descripción
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.
Gobierno corporativo
El ISS Governance QualityScore de ARYx Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
